Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Reviews R&D Thrust, Biosimilars Plan On Course

Executive Summary

Lupin is reorienting its R&D priorities with a thrust on more definitive, near and mid-term opportunities while rationalizing its discovery program and trimming its headcount. The firm’s biosimilars program though remains on track with a filing anticipated in Europe and Japan this fiscal.

You may also be interested in...



Cutbacks Rise As Indian Pharma Tightens Control On Costs

Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in a tough overall operating environment. Sun Pharma, which has declared an 'unwavering focus' on cost control, recently ended operations at two Indian clinical pharmacology units.

Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market

Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.

Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market

Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel